BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 1855324)

  • 1. The treatment of mesangial IgA nephropathy with cyclophosphamide, dipyridamole and warfarin.
    Woo KT; Lee GS
    Clin Nephrol; 1991 Apr; 35(4):184. PubMed ID: 1855324
    [No Abstract]   [Full Text] [Related]  

  • 2. The treatment of mesangial IgA nephropathy with cyclophosphamide, dipyridamole and warfarin: a two-year prospective trial.
    Walker RG; Yu SH; Owen JE; Kincaid-Smith P
    Clin Nephrol; 1990 Sep; 34(3):103-7. PubMed ID: 2225560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefit of cyclophosphamide therapy in IgA nephritis may have been obscured by warfarin-related nephropathy in the randomized trials in which warfarin and dipyridamole were used in combination with cyclophosphamide.
    Brodsky SV; Rovin BH; Hebert LA
    Nephrol Dial Transplant; 2012 Feb; 27(2):475-7. PubMed ID: 21948859
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of triple therapy on the progression of mesangial proliferative glomerulonephritis.
    Woo KT; Edmondson RP; Yap HK; Wu AY; Chiang GS; Lee EJ; Pwee HS; Lim CH
    Clin Nephrol; 1987 Feb; 27(2):56-64. PubMed ID: 3549083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Follow-up renal biopsies in IgA nephritic patients on triple therapy.
    Woo KT; Chiang GS; Lim CH
    Clin Nephrol; 1987 Dec; 28(6):304-5. PubMed ID: 3442958
    [No Abstract]   [Full Text] [Related]  

  • 6. Dipyridamole and low-dose warfarin without cyclophosphamide in the management of IgA nephropathy.
    Woo KT; Lee GS; Pall AA
    Kidney Int; 2000 Jan; 57(1):348-9. PubMed ID: 10712116
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of triple therapy in IgA nephritis: a follow-up study 5 years later.
    Woo KT; Lee GS; Lau YK; Chiang GS; Lim CH
    Clin Nephrol; 1991 Aug; 36(2):60-6. PubMed ID: 1934661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized controlled trial of cyclophosphamide, warfarin and dipyridamole in idiopathic membranous glomerulonephritis.
    Murphy BF; McDonald I; Fairley KF; Kincaid-Smith PS
    Clin Nephrol; 1992 May; 37(5):229-34. PubMed ID: 1606772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A case of IgA nephritis showing diffuse podocytic detachment from the glomerular basement membrane.
    Moriya T; Nakazawa K; Itoh N; Shigematsu H; Higuchi M; Miyasaka M; Oguchi H
    Nihon Jinzo Gakkai Shi; 1992 Apr; 34(4):423-30. PubMed ID: 1635288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of treatment with prednisolone or cyclophosphamide-warfarin-dipyridamole combination on the outcome of patients with membranous nephropathy.
    Shearman JD; Yin ZG; Aarons I; Smith PS; Woodroffe AJ; Clarkson AR
    Clin Nephrol; 1988 Dec; 30(6):320-9. PubMed ID: 3243041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controlled trial of dipyridamole and low-dose warfarin in patients with IgA nephritis with renal impairment.
    Lee GS; Woo KT; Lim CH
    Clin Nephrol; 1989 May; 31(5):276. PubMed ID: 2661066
    [No Abstract]   [Full Text] [Related]  

  • 12. Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial.
    Yoshikawa N; Honda M; Iijima K; Awazu M; Hattori S; Nakanishi K; Ito H;
    Clin J Am Soc Nephrol; 2006 May; 1(3):511-7. PubMed ID: 17699253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group.
    Yoshikawa N; Ito H; Sakai T; Takekoshi Y; Honda M; Awazu M; Ito K; Iitaka K; Koitabashi Y; Yamaoka K; Nakagawa K; Nakamura H; Matsuyama S; Seino Y; Takeda N; Hattori S; Ninomiya M
    J Am Soc Nephrol; 1999 Jan; 10(1):101-9. PubMed ID: 9890315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined therapy in children and adolescents with IgA nephropathy.
    Murakami K; Yoshioka K; Akano N; Takemura T; Okada M; Aya N; Hino S; Miyazato H; Yagi K; Maki S
    Nihon Jinzo Gakkai Shi; 1994 Jan; 36(1):38-43. PubMed ID: 8107307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined therapy with prednisolone, azathioprine, heparin-warfarin, and dipyridamole for paediatric patients with severe IgA nephropathy--is it relevant for adult patients?
    Yoshikawa N; Ito H
    Nephrol Dial Transplant; 1999 May; 14(5):1097-9. PubMed ID: 10344344
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term results of a randomized controlled trial in childhood IgA nephropathy.
    Kamei K; Nakanishi K; Ito S; Saito M; Sako M; Ishikura K; Hataya H; Honda M; Iijima K; Yoshikawa N;
    Clin J Am Soc Nephrol; 2011 Jun; 6(6):1301-7. PubMed ID: 21493743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IgA nephritis in Singapore: clinical, prognostic indices, and treatment.
    Woo KT; Chiang GS; Lau YK; Lim CH
    Semin Nephrol; 1987 Dec; 7(4):379-81. PubMed ID: 3445021
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical effect of dipyridamole in patients with IgA nephropathy.
    Yagame M; Tomino Y; Miura M; Suga T; Endoh M; Nomoto Y; Sakai H
    Tokai J Exp Clin Med; 1986 Nov; 11(5):329-33. PubMed ID: 2960035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapidly progressive glomerulonephritis: treatment with combined immunosuppression and anticoagulation with arvin.
    Segasothy M; Kong CT; Morad Z; Suleiman AB; Phang KS
    Singapore Med J; 1986 Oct; 27(5):422-7. PubMed ID: 3823948
    [No Abstract]   [Full Text] [Related]  

  • 20. An adolescent with IgA nephropathy and Crohn disease: pathogenetic implications.
    Takemura T; Okada M; Yagi K; Kuwajima H; Yanagida H
    Pediatr Nephrol; 2002 Oct; 17(10):863-6. PubMed ID: 12376818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.